Reshaping the HIV treatment and prevention landscape
Otilimab (anti-GM-CSF): novel MoA to address unmet
need in rheumatoid arthritis (RA)
Ph2 data shows potential for
differentiation on pain
-
-
Despite many treatments available ~40% of patients on a
biologic report daily pain; a key driver for switching²
Ph2 otilimab data suggest superiority on CDAI and pain
New mechanism for significant
unmet patient need
- ~50m people have RA globally1
-
-
gsk
~30% of RA patients achieve remission so new MoAs are important
Phase 3 data expected end 2022
LS mean (SE) change from baseline in CDAI
-10
-15
-20
-25
-30
5
5
LO
W1
W2
***p<0.001 vs placebo
CDAI response using the Phase 2 EOW dosing regimen
T-4.95
-17.14***
W4
W6
W8
-6.59
Placebo
Otilimab 22.5 mg
Study
ContRAst-1
Design
Otilimab 45 mg
ContRAst-2
Otilimab 90 mg
Otilimab 135 mg
ContRAst-3
***
-23.23**
-Otilimab 180 mg
W12
Endpoints
Otilimab vs tofacitinib (JAKI) in combination with
methotrexate (MTX) in patients in inadequate
response (IR) to biologic or JAKi
Otilimab vs tofacitinib (JAKI) in patients in IR to
DMARDs
Primary: ACR20 vs
placebo at week 12
Key secondary: pain
and CDAI vs active
comparator
Otilimab vs sarilumab (IL-6) in patients with IR to
biological DMARDs and/or JAKI
1. Gibofsky A, Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis, 2012 Dec; 18(13 Suppl):S295-302;
2. Targeted treatments for rheumatoid arthritis, Novel treatment strategies in rheumatoid arthritis, Gerd R Burmester, Janet E Pope; Adelphi RA DSP 2016 3. October 07,
2020, https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30229-0/fulltext
98View entire presentation